

BioDE Ventures Ltd.

NEWS RELEASE

Vancouver, B.C. February 9, 2017 – BioDE Ventures Ltd. (the “**Company**”) announces that further to the news release dated January 30, 2017 it has closed the second tranche of its private placement announced in its news release dated November 18, 2016.

In the second tranche of this financing, the Company has raised a total of \$250,680 through the distribution of 1,566,750 special warrants (“**Special Warrants**”) of the Company at a price of \$0.16 per Special Warrant.

In both tranches, the Company has raised a total of \$373,580.00 through the distribution of 2,334,875 Special Warrants of the Company at a price of \$0.16 per Special Warrant.

Each Special Warrant entitles the holder to receive, without payment of any additional consideration or need for further action, one common share (“**Share**”) of the Company. The Special Warrants will convert to Shares at the earlier of:

- a) 10 business days from the effective date of the three cornered amalgamation pursuant to the three cornered amalgamation agreement between the Company, Exro Technologies Inc. and 1089001 dated November 7, 2016 (the “**Amalgamation Agreement**”);
- b) the date of the cancellation of the Amalgamation Agreement;
- c) the date the board of directors of BioDE at its own discretion decides to convert the special warrants into common shares; and
- d) one year from the date of the issuances of the special warrants.

A finder’s fees of in the total amount of \$15,344 and 76,720 brokers warrants are payable in relation to this financing. Brokers warrants will be issued at the effective date of the Amalgamation Agreement, will have an exercise price of \$0.20 and will expire in two years.

The securities issued in relation to the first tranche of this financing are subject to a regulatory four-month hold period expiring May 31, 2017, and in relation to the second tranche of this financing are subject to a regulatory four-month hold period expiring June 10, 2017.

The net proceeds of the offering, together with the Company’s current capital, will be used by the Company to advance additional funds to Exro Technologies Inc. and pay for costs associated with the Amalgamation Agreement.

Effective January 25, 2017 the Company appointed Jonathan Ritchey as the Chief Technology Officer of the Company. Mr. Ritchey is the founder and Chief Scientist of Exro Technologies Inc. (“Exro”), an entrepreneur, business owner and custodian of the Exro's intellectual property and patent portfolio. Jonathan's skills and experience are very important to the needs of the Company.

ON BEHALF OF THE BOARD

Chester Shynkaryk

Chief Executive Officer

Phone: 604-722-9140

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. **This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.**

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.